Article
Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age.
AIDS (London, England) - 15 Mar 2022
Nikanjam Mina, Tran Lana, Chadwick Ellen G, Bwakura-Dangarembizi Mutsa, Bolton Moore Carolyn, Samson Pearl, Spector Stephen A, Chakhtoura Nahida, Jean-Philippe Patrick, Frenkel Lisa, Zimmer Bonnie, Benns Alex, Libous Jennifer, Capparelli Edmund V
Abstract excerpt
OBJECTIVE: Dosing efavirenz (EFV) in children less than 3 years of age is challenging due to large variability in drug levels. This study evaluated differences in pharmacokinetics with tuberculosis (TB) therapy, formulation, age, and CYP2B6 genotype. DESIGN: Pharmacokinetic data from three IMPAACT/PACTG studies (P382, P1021, and P1070) for children initiating therapy less than 40 months of age were evaluated....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.